Allergic reactions to nonsteroidal anti-inflammatory drugs: Is newer better?

Current Allergy and Asthma Reports

Volumn 7, Issue 1, 2007, Pages 35-40

  Berges Gimeno, M Pilar ^a   Martín Lázaro, Joaquín ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; IMRECOXIB; LUMIRACOXIB; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGENASE INHIBITOR; PARACETAMOL; PARECOXIB; PLACEBO; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLONE DERIVATIVE; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CLINICAL TRIAL; CROSS REACTION; DESENSITIZATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; HUMAN; IMMUNOPATHOGENESIS; LOW DRUG DOSE; NOSE POLYP; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SKIN MANIFESTATION; URTICARIA;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG HYPERSENSITIVITY; HUMANS; URTICARIA;

EID: 34247504566     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-007-0028-9     Document Type: Review

References (39)

1. Stevenson D, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001, 87:177-180.
2. McDonald JR, Mathison DA, Stevenson DD: Aspirin intolerance in asthma, detection by oral challenge. J Allergy Clin Immunol 1972, 50:198-207.
3. Christie PE, Tagari P, Ford-Hutchinson AW, et al.: Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991, 143:1025-1029.
4. Berges-Gimeno MP, Simon RA, Stevenson DD: The natural history and clinical characteristics-of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunology 2002, 89:474-478.
5. Szczeklik A, Nizankowska M, Duplaga M, et al.: Natural history of aspirin-induced asthma. Eur Respir J 2000, 16:432-436.
6. Mastarlerz L, Setkowicz M, Sanak M, Szczeklik A: Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004, 113:771-775.
7. Mathison DA, Lumry WR, Stevenson DD, et al.: Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitization. J Allergy Clin Immunol 1982, 69:135.
8. Szczeklik A: Analgesics, allergy and asthma. Drugs 1986, 4:148-163.
9. Daxum Z, Becker WM, Schulz KH, Schlaak M: Sensitivity to aspirin: a new serologic diagnostic method. J Investigational Allergol Clin Immunol 1993, 3:72-78.
10. Kowalski ML, Bienkiewicz B, Woeszcek G: Diagnosis of pyrazolone drug sensitivity: clinical history versus skin testing and in vitro testing. Allergy Asthma Proc 1999, 20:347-352.
11. Asero R: Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003, 111:1095-1098.
12. Levy M, Fink J: Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001, 87:72-73.
13. Grob M, Pichler WJ, Wuthrich B: Anaphylaxis to celecoxib. Allergy 2002, 57:264-265.
14. Fontaine C, Bousquet PJ, Demoly P: Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. J Allergy Clin Immunol 2005, 115:633-634.
15. Szczeklik A, Stevenson DD: Aspirin induced asthma: advances and pathogenesis and management. J Allergy Clin Immunol 1999, 104:5-13.
16. Yoshida S, Ishizaki Y, Omuma K: Selective cyclooxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000, 106:1201-1202.
17. Dahlen B, Szczeklik A, Murray JJ: Celecoxib in patients with asthma and aspirin intolerance. New Engl J Med 2001,344:142.
18. Szczeklik A, Nizankowska E, Bochenek G, et al.: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001, 31:219-225.
19. Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001, 108:47-51.
20. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002, 46:2201-2206.
21. Martín-García C, Hinojosa M, Berges P, et al.: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002, 121:1812-1817.
22. Martín-García C, Hinojosa M, Berges P, et al.: Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol 2003, 13:20-25.
23. Gyllfors P, Bochenek G, Overholt J, et al.: Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003, 111:1116-1121.
24. Valero A, Enrique E, Baltasar M, et al.: Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions. Med Clin (Barc) 2003, 121:695-696.
25. Woessner KM, Simon RA, Stevenson DD: Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2004, 93:339-344.
26. Micheletto C, Tognella. S, Guerriero M, Dal Negro R: Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. Allerg Immunol (Paris) 2006, 38:10-14.
27. Asero R: Tolerability of rofecoxib. Allergy 2001, 56:916-917.
28. Berges-Gimeno MP, Camacho-Garrido E, García-Rodríguez RM, et al.: Rofecoxib safe in NSAID hypersensitivity. Allergy 2001, 56:1017-1018.
29. Nettis E, Di PR, Ferrannini A, Tursi A: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002, 88:331-334.
30. Pacor ML, Di Lorenzo G, Biasi D, et al.: Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002, 32:397-400.
31. Quiralte J, Saenz de San Pedro B, Florido JJ: Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002, 89:63-66.
32. García-Rodríguez RM, Hinojosa M, Camacho-Garrido E, Berges Gimeno P, Martín García C. Celecoxib, safe in NSAID intolerance. Allergy 2002; 57:1085-6.
33. Nettis E, Colanardi MC, Ferrannini A, Tursi A: Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005, 94:29-33.
34. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Safety of etoricoxib, a new cyclooxygcnase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005, 95:154-158.
35. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005, 94:34-38.
36. Quiralte J, Delgado J, Saenz de San Pedro B, et al.: Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004, 93:360-364.
37. Simon RA: Adverse respiratory reactions to Aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004, 4:17-24.
38. Berges-Gimeno MP, Simon R A, Stevenson DD: Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003, 90:338-341.
39. Berges-Gimeno MP, Simon RA, Stevenson DD: Long term treatment with aspirin desensitization in asthmatics with aspirin exacerbated respiratory disease. J Allergy Clin Immunol 2003, 111:180-186.